Blood-brain barrier penetration of non-replicating SARS-CoV-2 and S1 variants of concern induce neuroinflammation which is accentuated in a mouse model of Alzheimer’s disease

[1]  W. Banks,et al.  Characteristics of Exosomes and the Vascular Landscape Regulate Exosome Sequestration by Peripheral Tissues and Brain , 2022, International journal of molecular sciences.

[2]  M. Glatzel,et al.  Young COVID-19 Patients Show a Higher Degree of Microglial Activation When Compared to Controls , 2022, Frontiers in Neurology.

[3]  Huanchun Chen,et al.  SARS-CoV-2 productively infects human brain microvascular endothelial cells , 2022, Journal of neuroinflammation.

[4]  Zhihan Zhao,et al.  Nervous system manifestations related to COVID-19 and their possible mechanisms , 2022, Brain Research Bulletin.

[5]  C. Steves,et al.  Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 , 2022, The Lancet.

[6]  Jaemyun Lyu,et al.  SARS-CoV-2 Infection of Microglia Elicits Proinflammatory Activation and Apoptotic Cell Death , 2022, Microbiology spectrum.

[7]  Y. Tizabi,et al.  Neuropathological Aspects of SARS-CoV-2 Infection: Significance for Both Alzheimer’s and Parkinson’s Disease , 2022, Frontiers in Neuroscience.

[8]  C. Steves,et al.  Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study , 2022, The Lancet.

[9]  S. Tagliaferri,et al.  Sex-Related Differences in Long-COVID-19 Syndrome. , 2022, Journal of women's health.

[10]  R. Kream,et al.  Reassessment of the blood-brain barrier: a potential target for viral entry into the immune-privileged brain. , 2022, Germs.

[11]  T. Vinař,et al.  Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern , 2022, eBioMedicine.

[12]  T. Theoharides.  Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome? , 2022, Molecular Neurobiology.

[13]  S. Galetta,et al.  Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[14]  W. Banks,et al.  The next chapter for COVID-19: A respiratory virus inflames the brain , 2022, Brain, Behavior, and Immunity.

[15]  S. Maier,et al.  SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties , 2021, Brain, Behavior, and Immunity.

[16]  F. Müller,et al.  The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2 , 2021, Stem Cell Reports.

[17]  K. Kaila,et al.  APOE ε4 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study , 2021, Acta neuropathologica communications.

[18]  G. Nuovo,et al.  The histologic and molecular correlates of liver disease in fatal COVID-19 including with alcohol use disorder , 2021, Annals of Diagnostic Pathology.

[19]  I. Douglas,et al.  Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19 , 2021, JAMA network open.

[20]  E. Mazzon,et al.  SARS-CoV-2 Exacerbates Beta-Amyloid Neurotoxicity, Inflammation and Oxidative Stress in Alzheimer’s Disease Patients , 2021, International journal of molecular sciences.

[21]  S. Hsu,et al.  Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2 , 2021, Nature Chemical Biology.

[22]  N. Narayanan,et al.  COVID-19 Case Fatality and Alzheimer's Disease. , 2021, Journal of Alzheimer's disease : JAD.

[23]  Suji Kim,et al.  Spike Proteins of SARS-CoV-2 Induce Pathological Changes in Molecular Delivery and Metabolic Function in the Brain Endothelial Cells , 2021, Viruses.

[24]  M. Heneka,et al.  Longitudinal Neurocognitive and Pulmonological Profile of Long COVID-19: Protocol for the COVIMMUNE-Clin Study , 2021, JMIR research protocols.

[25]  H. Gao,et al.  SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration , 2021, Signal Transduction and Targeted Therapy.

[26]  J. Geddes,et al.  Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19 , 2021, PLoS medicine.

[27]  L. Gesualdo,et al.  Association between Long COVID and Overweight/Obesity , 2021, Journal of clinical medicine.

[28]  I. Pavord,et al.  Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients , 2021, Pragmatic and observational research.

[29]  Yun Wang,et al.  The Effects of Aβ1-42 Binding to the SARS-CoV-2 Spike Protein S1 Subunit and Angiotensin-Converting Enzyme 2 , 2021, International journal of molecular sciences.

[30]  Ryan J. Low,et al.  Characterizing long COVID in an international cohort: 7 months of symptoms and their impact , 2021, EClinicalMedicine.

[31]  L. McCullough,et al.  The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection , 2021, Current Neurology and Neuroscience Reports.

[32]  H. Bartsch,et al.  Long COVID in a prospective cohort of home-isolated patients , 2021, Nature Medicine.

[33]  N. Abdul Ghafoor,et al.  Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2’s pathogenicity factors , 2021, PloS one.

[34]  M. Murad,et al.  Post–COVID-19 Syndrome (Long Haul Syndrome): Description of a Multidisciplinary Clinic at Mayo Clinic and Characteristics of the Initial Patient Cohort , 2021, Mayo Clinic Proceedings.

[35]  S. Verjovski-Almeida,et al.  Dementia is an age‐independent risk factor for severity and death in COVID‐19 inpatients , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[36]  Danish Idrees,et al.  SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration , 2021, Biochemical and Biophysical Research Communications.

[37]  Irene B. Meier,et al.  Neurological and mental health consequences of COVID-19: potential implications for well-being and labour force , 2021, Brain communications.

[38]  S. Farhadian,et al.  Neuroinvasion of SARS-CoV-2 in human and mouse brain , 2021, The Journal of experimental medicine.

[39]  A. Castagna,et al.  Could COVID-19 anosmia and olfactory dysfunction trigger an increased risk of future dementia in patients with ApoE4? , 2021, Medical Hypotheses.

[40]  Peter J Hellyer,et al.  Cognitive deficits in people who have recovered from COVID-19 , 2020, EClinicalMedicine.

[41]  Ryan J. Low,et al.  Characterizing long COVID in an international cohort: 7 months of symptoms and their impact , 2020, EClinicalMedicine.

[42]  W. Banks,et al.  The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice , 2020, Nature Neuroscience.

[43]  S. Love,et al.  Cognitive impact of COVID-19: looking beyond the short term , 2020, Alzheimer's research & therapy.

[44]  A. Andrews,et al.  The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood–brain barrier , 2020, Neurobiology of Disease.

[45]  A. Verkhratsky,et al.  Psychiatric face of COVID-19 , 2020, Translational Psychiatry.

[46]  S. Farhadian,et al.  Neuroinvasion of SARS-CoV-2 in human and mouse brain , 2020, bioRxiv.

[47]  A. Andrews,et al.  The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in vitro models of the human blood–brain barrier , 2020, bioRxiv.

[48]  L. Montaner,et al.  Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts , 2020, Journal of leukocyte biology.

[49]  V. Regitz-Zagrosek,et al.  Impact of sex and gender on COVID-19 outcomes in Europe , 2020, Biology of Sex Differences.

[50]  E. Hascup,et al.  Does SARS-CoV-2 infection cause chronic neurological complications? , 2020, GeroScience.

[51]  F. Cheng,et al.  Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China , 2020, Clinical Microbiology and Infection.

[52]  Jing Shi,et al.  Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan , 2020, Journal of Allergy and Clinical Immunology.

[53]  A. Fagan,et al.  APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline , 2020, Nature.

[54]  A. Fagan,et al.  Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction , 2018, Nature Medicine.

[55]  J. Sundberg,et al.  Living inside the box: environmental effects on mouse models of human disease , 2018, Disease Models & Mechanisms.

[56]  Arthur W. Toga,et al.  Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.

[57]  C. Bocti,et al.  β-Amyloid peptides display protective activity against the human Alzheimer’s disease-associated herpes simplex virus-1 , 2015, Biogerontology.

[58]  J. Arnhold,et al.  Differences in innate immune response between man and mouse. , 2014, Critical reviews in immunology.

[59]  S. M. Robinson,et al.  Human Immunodeficiency Virus-1 Uses the Mannose-6-Phosphate Receptor to Cross the Blood-Brain Barrier , 2012, PloS one.

[60]  J. Morley,et al.  The SAMP8 mouse: a model to develop therapeutic interventions for Alzheimer's disease. , 2012, Current pharmaceutical design.

[61]  W. Banks,et al.  Lipopolysaccharide alters the blood–brain barrier transport of amyloid β protein: A mechanism for inflammation in the progression of Alzheimer’s disease , 2009, Brain, Behavior, and Immunity.

[62]  T. Cham,et al.  On-site preparation of technetium-99m labeled human serum albumin for clinical application. , 2007, The Tohoku journal of experimental medicine.

[63]  D. Butterfield,et al.  Adriamycin-induced, TNF-α-mediated central nervous system toxicity , 2006, Neurobiology of Disease.

[64]  D. Butterfield,et al.  Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. , 2006, Neurobiology of disease.

[65]  William A Banks,et al.  Blood-brain barrier transport of cytokines: a mechanism for neuropathology. , 2005, Current pharmaceutical design.

[66]  D. Borchelt,et al.  Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid β peptide in APPswe transgenic mice , 2003, Neurobiology of Disease.

[67]  W. Banks,et al.  Alzheimer’s disease through the eye of a mouse Acceptance lecture for the 2001 Gayle A. Olson and Richard D. Olson prize , 2002, Peptides.

[68]  W. Banks,et al.  Intravenous human interleukin-1alpha impairs memory processing in mice: dependence on blood-brain barrier transport into posterior division of the septum. , 2001, The Journal of pharmacology and experimental therapeutics.

[69]  W. Banks,et al.  Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice , 2000, Peptides.

[70]  J. Morley,et al.  Learning and memory in the SAMP8 mouse , 1997, Neuroscience & Biobehavioral Reviews.

[71]  A. Shilatifard,et al.  Complex-type N-linked oligosaccharides of gp120 from human immunodeficiency virus type 1 contain sulfated N-acetylglucosamine , 1993, Journal of virology.

[72]  H. Ushijima,et al.  Inhibition of Human Immunodeficiency Virus‐1 Infection by Human Conglutinin‐like Protein: In vitro Studies , 1992, Japanese journal of cancer research : Gann.

[73]  T. Mizuochi,et al.  Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. , 1988, The Biochemical journal.

[74]  D. Begley,et al.  Measurement of Solute Transport Across the Blood–Brain Barrier in the Perfused Guinea Pig Brain: Method and Application to N‐Methyl‐α‐Aminoisobutyric Acid , 1986, Journal of neurochemistry.

[75]  M. Marsh.  The entry of enveloped viruses into cells by endocytosis. , 1984, The Biochemical journal.

[76]  H. Davson.  Blood–brain barrier , 1977, Nature.

[77]  R. Montelaro,et al.  On the use of chloramine-T to iodinate specifically the surface proteins of intact enveloped viruses. , 1975, The Journal of general virology.